Which study design will be applied?

This is a double-blind, international study with study sites in Switzerland and Germany. Neither the parents of the included infants nor the physicians and nurses will know which treatment will be applied. Medication and placebo (medication without active ingredient) cannot be differentiated. Allocation to one or the other group will be done at random, which means that there is a probability of 50% for each infant being treated with erythropoietin.